Expression of DEK in pancreatic cancer and its correlation with clinicopathological features and prognosis

Ting Zhao¹*, Bijun Qiu²*, Senhao Zhou¹, Guoping Ding¹, Liping Cao¹, Zhengrong Wu¹

¹. Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China
². Jiangdu People’s Hospital Yangzhou, Yangzhou 225000, China

* These authors contribute to this paper equally

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2018.05.22; Accepted: 2019.01.09; Published: 2019.01.29

Abstract

Background: The oncogene DEK, which was originally identified as part of the protein product of the DEK-CAN fusion oncogene, has been shown to promote tumorigenesis in a variety of cancer cell types. However, little is known about the expression and role of DEK in pancreatic ductal adenocarcinoma (PDAC), which is one of the most refractory malignant tumors worldwide and has poor prognosis. Our study aimed to understand the role of DEK in the development and progression of pancreatic adenocarcinoma.

Materials and methods: We used western blotting and immunohistochemistry to examine the expression of DEK in pancreatic adenocarcinoma cells and tissues. We analyzed the correlation between DEK expression and clinicopathological characteristics and prognosis in 163 pancreatic adenocarcinoma patients.

Results: Protein levels of DEK in pancreatic adenocarcinoma tissues (76/136, 55.9%) were significantly higher than those in adjacent non-tumor tissues (16.2%, 22/136). A high expression level of DEK was associated with poor prognosis (P<0.001). In addition, the combination of CA19-9 and DEK expression (P<0.001) was a better prognostic indicator than CA19-9 expression alone (P=0.012).

Conclusions: DEK may play a significant role as a valuable biomarker in the development and progression of pancreatic adenocarcinoma. The combination of DEK and CA19-9 improves the prognostic prediction in patients with pancreatic adenocarcinoma.

Key words: DEK; Pancreatic adenocarcinoma; CA19-9; prognosis

Introduction

Pancreatic cancer is a common and refractory malignant tumor with an extremely poor prognosis [1-3]. The incidence of PDAC has been increasing worldwide with the growth and aging of the general population [4,5]. Statistics indicate that the 5-year survival rate of PDAC is only approximately 5%, with a mortality rate of nearly 85.3% among all newly diagnosed cases of PDAC [4]. Surgery remains the primary treatment for cases without distant metastasis. Since PDAC is often detected in an advanced stage with low resection rates, more effective screening techniques and a better understanding of the pathogenesis of PDAC are urgently needed.

The DEK gene is a putative proto-oncogene that encodes a 375-amino acid protein with an estimated
molecular weight of 43kDa [6-8]. DEK was first characterized as part of the protein product of the DEK-CAN fusion oncogene generated by a t(6;9) translocation involving breakpoints in the DEK gene on chromosome 6 and the CAN gene on chromosome 9 in a subset of patients with acute myelogenous leukemia [9,10]. Many studies have demonstrated the functions of DEK, including involvement in the regulation of hematopoiesis, chromatin reconstruction, gene transcription, and cell apoptosis [11-13]. Overexpression of DEK has been observed in several malignancies including breast cancer, melanoma, retinoblastoma, gastric adenocarcinoma, hepatocellular carcinoma, colorectal cancer, lung cancer, and bladder cancer [14-20], demonstrating its role in tumorigenesis and neoplastic progression [14,21-23].

The expression and role of DEK in pancreatic adenocarcinoma has rarely been reported. Through database analysis we found that DEK expression levels in PDAC tissues were much higher than those in non-tumor tissues. In this study we aimed to explore whether DEK expression is associated with clinicopathological features of pancreatic cancer and its prognostic value in this aggressive disease.

Materials and methods

Cell culture

Human pancreatic cancer cell line, including Panc-1, CFPAC-1, AsPC-1, SW1990, BxPC-3, MIAPaCa-2, and normal pancreatic ductal epithelial cells HPDE6-C7 are all obtained from Chinese Academy of Sciences (Shanghai, China). BxPC-3 and AsPC-1 cell lines were cultured in RPMI 1640 medium (Hyclone) containing 10% fetal bovine serum (FBS, Gibco, New York, USA). Panc-1, CFPAC-1, SW1990, MIAPaCa-2 and HPDE6-C7 cell lines were cultured in DMEM medium with 10% FBS.

Patients and clinicopathological parameters

One hundred and thirty six pancreatic ductal adenocarcinoma patients who had surgery between 2012 and 2016 were selected in Sir Run Run Shaw Hospital, affiliated with the Zhejiang University of Medicine, Zhejiang University. All participants or their guardians gave written consent of their tissue samples and medical information to be used for scientific research. We assessed the histological stage of PDAC patients on the basis of the newest TNM staging system by the American Joint Committee on Cancer (AJCC) in 2017.

Immunohistochemistry

Thin slices of tumor tissue from all cases were fixed in 4% formaldehyde solution (pH 7.0) for periods not exceeding 24 h. Paraffin embedding was conducted, and 4 μm thick sections were cut and placed on glass slides coated with 3-aminopropyl triethoxysilane (Seebio Biotech Inc., Shanghai, China) for immunohistochemistry. Tissue samples were stained with hematoxylin and eosin to determine histological type and grade of tumors. Briefly, pancreatic ductal adenocarcinoma tissues were cut at a thickness of 4 μm using a cryostat. The sections were mounted on microscope slides, air-dried and then fixed in a mixture of 50% acetone and 50% methanol. The sections were then de-waxed with xylene, gradually hydrated with gradient alcohol, and washed with phosphate-buffered saline (PBS). Sections were incubated for 60 min with the primary antibody. Following washing with PBS, sections were incubated for 30 min with the secondary biotinylated antibody (Multilink Swine anti-goat/mouse/rabbit immunoglobulin; Dako Inc., Carpinteria, CA, USA). Following washing, Avidin Biotin Complex (1:1,000 dilution, Vector Laboratories Ltd., Burlingame, CA, USA) was then applied to the sections for 30-60 min at room temperature. The immunoreactive products were visualized by catalysis of 3, 3-diaminobenzidine (DAB) by horseradish peroxidase in the presence of H2O2 following extensive washings. Sections were then counterstained in Gill’s hematoxylin and dehydrated in ascending grades of methanol prior to clearing in xylene, and mounting under a coverslip. The sections were observed under an Olympus CX31 microscope (Olympus, Tokyo, Japan).

To score DEK as immunopositive staining, expression was classified semi-quantitatively. The staining density was scored as: 0 indicates negative, no or less than 5% positive cells, 1 indicates 5-25% positive cells, 2 indicates 26-50% positive cells and 3 indicates more than 50% positive cells. The dominant staining intensity was scored as: 0 indicates negative; 1 indicates weak; 2 indicates intermediate; and 3 indicates strong staining intensity. Expression was calculated by adding density score (0-3) and intensity score (0-3) before categorizing into low and high expression. High expression was defined as score≥3.
Western blot analysis

For western blot analysis, proteins were separated on 10% SDS-PAGE gels and transferred to a polyvinylidene difluoride membrane. After blocking, the membrane was incubated with an anti-DEK antibody (1:1,000; ab166624; Abcam, Cambridge, MA, USA) at 4°C overnight. After washing, the membrane was incubated with the secondary goat anti-rabbit antibodies conjugated with horseradish peroxidase (1:5 000, Pierce, USA) for 1 h at room temperature. Densitometry was performed using Kodak X-OMAT LS film (Eastman Kodak, Rochester, NY).

Statistical analysis

All data was analyzed by the SPSS version 20.0. We use Kaplan–Merier method to analyze patient survival, and the differences in survival were evaluated using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model to confirm factors independently associated with survival. The paired-samples t-test was used to compare the intensity ratio between cancer tissues and matching non-cancerous livers. All p-values were based on two-sided statistical analyses and the rate of P<0.05 was considered to indicate a statistically significant difference.

Results

DEK is over-expressed in pancreatic cancer.

Analysis of chip results of 78 samples in the database GSE15471, which is one of the GEO database, including 39 cases of pancreatic cancer and 39 cases of corresponding non-tumor normal tissues, revealed that the expression of DEK in pancreatic cancer was significantly higher than that in corresponding non-tumor tissues (Fig. 1A). The expression of DEK in six pancreatic cancer cell lines was detected by western blotting, with normal pancreatic ductal epithelial cells HPDE6-C7 used as controls. The expression of DEK in pancreatic cancer cell lines was significantly increased relative to controls (Fig. 1B). Immunohistochemical examination showed that DEK was mainly located in the nuclei of PDAC cells, and the expression of DEK protein was significantly higher in PDAC tissues (55.9%, 76/136) compared with matched non-tumor tissues(22/136, 16.2%, Fig. 1 C,D).

Fig. 1. Expression of DEK in pancreatic ductal adenocarcinoma compared with corresponding normal pancreas. (A) Expression of DEK in pancreatic cancer and normal pancreas according to the database GSE15471, which is one of the GEO database. The mRNA expression of DEK is up-regulated in pancreatic cancer tissues (T) compared with the adjacent non-tumor tissues (N) using the GSE15471 dataset. (B) The expression of DEK in one normal pancreatic duct epithelial cell line and six pancreatic cancer cell lines detected by Western Blot. (C) Immunohistochemical detection of the DEK protein expression in PDAC tissue and corresponding normal tissue (original magnification, 100×and 400×); (D) Expression levels of DEK in pancreatic cancer tissues and the adjacent non-tumor tissues.
Table 1. Relationship between DEK protein expression and clinicopathological features of PDAC

| Characteristic        | (n)    | DEK expression | P value |
|-----------------------|--------|----------------|---------|
|                       | T36    | Low | High |         |
| Age                   |        |     |      | 0.139  |
| ≤58                   | 72     | 28  | 44   |        |
| >58                   | 64     | 32  | 32   |        |
| Gender                |        |     |      | 0.248  |
| Man                   | 80     | 32  | 48   |        |
| Women                 | 56     | 28  | 28   |        |
| Tumor size            |        |     |      | 0.038* |
| ≤3cm                  | 68     | 36  | 32   |        |
| >3cm                  | 68     | 24  | 44   |        |
| Differentiation       |        |     |      | <0.001*|
| Poor                  | 60     | 4   | 56   |        |
| Well and moderate     | 76     | 56  | 20   |        |
| Tumor Stage           |        |     |      | 0.002* |
| I, II                 | 80     | 44  | 36   |        |
| III, IV               | 56     | 16  | 40   |        |
| Lymph node metastasis |        |     |      | 0.001* |
| NO                    | 68     | 40  | 28   |        |
| YES                   | 68     | 20  | 48   |        |
| Distant metastasis    |        |     |      | 0.101  |
| M0                    | 120    | 56  | 64   |        |
| M1                    | 16     | 4   | 12   |        |
| CA19-9                |        |     |      | 0.099  |
| ≤37 IU/ml             | 80     | 40  | 40   |        |
| >37 IU/ml             | 56     | 20  | 36   |        |

* P < 0.05

Correlation between DEK overexpression and clinicopathological features

We analyzed immunohistochemistry data to investigate the relationship between DEK expression and clinicopathological features. High expression of DEK was significantly associated with differentiation status (P<0.001), lymph node metastasis (P<0.001), tumor stage (P=0.002), and tumor size (P=0.038) in our 163 PDAC patients (Table 1, Fig. 2). No significant correlation was observed between high DEK expression and other clinical characteristics of patients with PDAC, such as gender (P=0.248), age (P=0.139), or serosal invasion (P=0.101, Table 1).

Correlation between DEK overexpression and prognosis of PDAC patients

We also analyzed the correlation between DEK expression level and the prognosis of PDAC patients. In univariate analysis, PDAC patients with high tumor expression of DEK had significantly lower median survival time than those with low DEK expression (P<0.001, Table 2). These data suggest that DEK might be a valuable prognostic factor in PADC. We also found that tumor size (P<0.001), differentiation (P<0.001), distant metastasis (P=0.032), and high level of CA19-9 (P<0.012) correlated with survival (Table 2). Multivariate Cox regression analysis identified DEK expression (P=0.002) and high level of CA19-9 (P=0.037) as independent prognostic factors of survival (Table 3).

Fig. 2. Expression levels of DEK in pancreatic cancer tissues with different tumor differentiation and tumor stage. (A) Typical pictures of DEK expression with different pancreatic tumor differentiation. (B) Typical pictures of DEK expression with different tumor stage.

http://www.jcancer.org
The CA19-9 expression level is increased in most cancer patients but especially in those with pancreatic cancer, and CA191-9 is the most sensitive marker in PDAC reported to date. Our results indicate that the combination of CA19-9 and DEK expression (P<0.001) is a better indicator of prognosis in PDAC patients than CA19-9 alone (P=0.012, Fig. 3).

**Discussion**

PDAC is one of the most malignant cancers and has a 1-year survival rate of less than 20% and 5-year survival rate of less than 5% [24]. It is the fourth leading cause of cancer-related death in Western societies [25]. Surgery provides the only chance of cure; however, the majority of patients are diagnosed with metastasis or invasion of the superior mesenteric artery or celiac trunk and are not candidates for surgical resection of the tumor [26]. Even if resection can be achieved, the survival rate is still low [27]. Consequently, it is very important to find novel strategies for detection of PDAC in the early stage and thus improve the prognosis of patients.
DEK was identified as a putative proto-oncogene that can be linked to cancer through multiple mechanisms including cell division, DNA repair, aging, apoptosis, differentiation, or oncogenic transformation [28-30]. Many studies have reported the expression of DEK in different cancers. Khodadoust et al. suggested that the expression level of DEK is a useful tool for distinguishing benign nevi from malignant melanomas [31]. Ying et al. recently reported that DEK expression correlated with chemotherapy resistance and may be an independent prognostic factor for breast cancer, as well as a potential therapeutic target [14]. Moreover, studies in retinoblastoma patients identified DEK as a potential target on chromosome 6p22 and suggested that a gain of DEK function enhances tumor development, with similar findings in patients with bladder cancer [1]. Increasing evidence of a relationship between tumor type and DEK protein expression indicates the potential of DEK as a tumor marker [32].

A previous report by Sun et al. showed correlations between DEK expression and clinical pathological parameters and prognosis [33]. The overall goal of our study was to further determine the effect of DEK expression on the prognosis of pancreatic cancer. We performed immunohistochemical staining of DEK protein and survival data analysis using 136 PDAC tissues and their adjacent normal tissue counterparts. DEK protein was mainly expressed in the nucleus, and the expression of DEK protein was significantly higher in cancer tissues than adjacent tumor tissues. Sun's research showed that high expression of DEK was significantly related to differentiation status, tumor stage, and tumor size. In addition to that, our study also found the relationship between the high expression of DEK and the lymph node metastasis. Consistent with the results of Sun's study, our study also indicated that patients with high expression of DEK had a significantly lower median survival time, which validated DEK as a valuable prognostic factor in PDAC. Besides, we also showed that the expression level of DEK was significantly related to the CA19-9 expression level, and might be used as an important supplement to CA19-9 in the diagnosis of PDAC.

In summary, overexpression of DEK correlated with tumor size, differentiation, tumor stage, and lymph node metastasis, indicating the important role of DEK protein in the progression of PDAC. The combination of DEK expression and CA19-9 expression levels represents a better prognostic index than CA19-9 alone. DEK may potentially be used as a biomarker for prognostic evaluation and a molecular therapeutic target in PADC patients.

Acknowledgements

This research was supported by the Major Research Project of Science Technology Department of Zhejiang Province (2015C03G2010160), A Project Supported by Scientific Research Fund of Zhejiang Provincial Education Department (Y201534615), and the Foundation Project for Medical Science and Technology of Zhejiang province (2015KYB218).

Competing Interests

The authors have declared that no competing interest exists.

References

[1] Wise-Draper TM, Allen HV, Jones EE, et al. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol. 2006;26(20):7506-7519.
[2] Lehr JM. Medical treatment of pancreatic cancer. Expert Rev Anticancer Ther. 2007;7(4):533-544.
[3] Yeh JJ, Der CJ. Targeting signal transduction in pancreatic cancer treatment. Expert Opin Ther Targets. 2007;11(5):673-694.
[4] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
[5] Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
[6] Riveiro-Falkenbach E, Soengas MS. Control of tumorigenesis and chemoresistance by the DEK oncogene. Clin Cancer Res. 2010;16(11):2932-2938.
[7] Privette Vinnedge LM, Ho SM, Wikenheiser-Brokamp KA, et al. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer. PLoS One. 2012;7(10):e46895.
[8] Privette Vinnedge LM, Benight NM, Wagh PK, et al. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer. PLoS One. 2012;7(10):e46895.
[9] von Lindern M, Fornerod M, van Baal S, et al. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol. 1992;12(4):1687-1697.
[10] Broxmeyer HE, Mor-Vaknin N, Kappes F, et al. Concise review: role of DEK in stem/progenitor cell biology. Stem Cells. 2013;31(8):1447-1453.
[11] Li X, Zhang W, Zhou L, et al. Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and NuTlin-3 depending on p53 status. Cancer Biol Ther. 2012;13(14):1522-1528.
[12] Ying G, Wu Y. DEK: A novel early screening and prognostic marker for breast cancer. Mol Med Rep. 2015;12(4):1687-1697.
[13] Piao J, Shang Y, Liu S, et al. High expression of DEK predicts poor prognosis of gastric adenocarcinoma. Diagn Pathol. 2014;9:67.
[14] Lin L, Piao J, Gao W, et al. DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer. 2013;13:366.
[15] Li X, Zhang W, Zhou L, et al. MicroRNA-592 targets DEK oncogene and suppresses cell growth in the hepatocellular carcinoma cell line HepG2. Int J Clin Exp Pathol. 2015;8(10):12455-12463.
[16] Datta A, Adelson ME, Mogilevkin Y, et al. Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer. BMC Cancer. 2011;11:234.
[17] Carro MS, Spiga FM, Quarto M, et al. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 2009;8(11):1202-1207.
[18] Krones RA, Jastrow A, McLone MG, et al. The identification of novel therapeutic targets for the treatment of malignant brain tumors. Cancer Lett. 2000;156(2):191-198.
[19] Alexiadis V, Waldmann T, Andersen J, et al. The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner. Genes Dev. 2000;14(11):1308-1312.
[20] Vance EB, Wagner NN. Written descriptions of orgasm: a study of sex differences. Arch Sex Behav. 1976;5(1):87-98.
[21] Sood AK, Suman VJ, Barlow CL, et al. Intron removal requires proofreading of U2AF/3' splice site recognition by DEK. Science. 2006;312(5782):1961-1965.
[22] Carro MS, Spiga FM, Quarto M, et al. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 2009;8(11):1202-1207.
[23] Soares LM, Zanier K, Mackereth C, et al. Intron removal requires proofreading of U2AF/3’ splice site recognition by DEK. Science. 2006;312(5782):1961-1965.
[24] German RR, Fink AK, Heron M, et al. The accuracy of cancer mortality statistics based on death certificates in the United States. Cancer Epidemiol. 2011;35(2):126-131.
[25] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):10-29.
[26] Senes SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189(1):1-7.
[27] Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200-1210.
[28] Kavanagh CM, Wise-Draper TM, Morreale RJ, et al. The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res. 2011;39(17):7465-7476.
[29] Stadler RB, Wicha MS, Jove R, et al. Cruciform structures are a common DNA feature important for regulating biological processes. BMC Mol Biol. 2011;12:33.
[30] Fahrer J, Popp O, Malanga M, et al. High-affinity interaction of poly(ADP-ribose) and the human DEK oncoprotein depends upon chain length. Biochemistry. 2010;49(33):7119-7130.
[31] Khodadoust MS, Verhaegen M, Kappes F, et al. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res. 2009;69(16):6405-6413.
[32] Zheng J, Kohler ME, Chen Q, et al. Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen. BMC Immunol. 2007;8:4.
[33] Sun J, Bi F, Yang Y, et al. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. Oncol Rep. 2017;37(2):857-864.